Brought to you by 
Roche gets ex-US rights to Genentech's Avastin
31 Jan 2005
Executive Summary
Roche has licensed all ex-US rights from Genentech to Avastin (bevacizumab), in Phase III for metastatic colorectal cancer. It paid $188mm up front, provides 75% of all global development costs, plus pays royalties on its net sales.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche gets ex-US rights to Genentech's Avastin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice